Dexcom (DXCM) Gains from Sales and Divestitures (2012)
Dexcom (DXCM) reported Gains from Sales and Divestitures of $900000.0 for Q4 2012.
Dexcom (DXCM) has 1 years of Gains from Sales and Divestitures data on file, last reported at $900000.0 in Q4 2012.
- Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $900000.0 in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $900000.0 (changed N/A YoY) and the FY2012 annual result came in at $900000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures held at $900000.0 in Q4 2012 per DXCM's latest filing.
- Across five years, Gains from Sales and Divestitures topped out at $900000.0 in Q4 2012 and bottomed at $900000.0 in Q4 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 900,000.00 |
| Dec 31, 2012 | 900,000.00 |